15. A variant IgG_1 comprising a human IgG_1 Fc region comprising amino acid substitutions relative to a wild-type human IgG_1 Fc region at amino acid residues 308 and 434, numbered according to the EU index as in Kabat, wherein the variant IgG_1 has an increased half-life compared to the half-life of an IgG_1 having the wild-type human IgG_1 Fc region, and wherein the amino acid substitution at amino acid residue 308 is a substitution with proline, and the amino acid substitution at amino acid residue 434 is a substitution with alanine.

16. ~~A method of treating tumor in a subject, said method comprising administering to the subject an effective amount of a~~A variant IgG of claim 1 or 3 for use in treating tumor in a subject.

17. ~~A method of inhibiting VEGF activity in a subject, said method comprising administering to said subject an effective amount of a~~A variant IgG of claim 1 or 3 for use in inhibiting VEGF activity in a subject.

18. The ~~method~~ variant IgG of claim 17, wherein the VEGF activity is angiogenesis.

19. ~~A method of modulating vascular permeability in a subject, said method comprising administering to said subject an effective amount of a~~A variant IgG of claim 1 or 3 for use in modulating vascular permeability in a subject.

20. ~~A method of inhibiting or preventing growth of cancer cells in a subject, said method comprising administering to said subject an effective amount of a~~A variant IgG of claim 1 or 3 for use in inhibiting or preventing growth of cancer cells in a subject.

21. The ~~method~~ variant IgG of claim 16, 17, 19 or 20, wherein the variant IgG is to be administered to the subject every 4 weeks or longer.